Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Inflammatory Bowel Disease V: Surgical Management01:21

Inflammatory Bowel Disease V: Surgical Management

145
Surgical interventions for inflammatory bowel disease (IBD), which includes ulcerative colitis and Crohn's disease, are essential in managing symptoms and addressing complications. The selection of surgical procedures is contingent upon the specific conditions and complications that stem from these illnesses.
Here are some common surgical interventions for IBD:
145
Drugs for Treatment of Ulcerative Colitis in IBD01:29

Drugs for Treatment of Ulcerative Colitis in IBD

136
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
136
Inflammatory Bowel Disease IV: Pharmacological Management01:29

Inflammatory Bowel Disease IV: Pharmacological Management

126
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
126
Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy01:30

Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy

331
Various diagnostic tests are employed in the diagnostic process for Inflammatory Bowel Disease (IBD), particularly to differentiate between Crohn's disease and ulcerative colitis.
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
331
Peptic Ulcer Disease IV: Management01:26

Peptic Ulcer Disease IV: Management

89
Medical treatment strategies for peptic ulcers encompass various methods. The primary goal of treatment is to diminish gastric acidity and strengthen mucosal defense mechanisms.
The therapeutic approach involves ensuring adequate rest, implementing drug therapy, promoting smoking cessation, making dietary modifications, and emphasizing long-term follow-up care.
Pharmacological management
The prevailing therapy for peptic ulcers involves a combination of managing the patient's current...
89
Inflammatory Bowel Disease I: Ulcerative Colitis01:27

Inflammatory Bowel Disease I: Ulcerative Colitis

166
Introduction
Inflammatory bowel disease, or IBD, encompasses a group of disorders characterized by chronic inflammation or ulceration of the gastrointestinal tract.
Risk Factors
The exact cause of IBD remains unclear, although it is believed to be due to a mix of genetic, environmental, microbial, and immune factors. Genetic factors are significant in determining susceptibility to IBD, with family history being a critical risk factor. Individuals with a first-degree relative who has IBD are at...
166

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Impact of BECLIN1 haploinsufficiency on goblet cell function and susceptibility to colitis.

Cell death & disease·2026
Same author

Reply.

Gastroenterology·2026
Same author

Rethinking the dose: A Bayesian meta-analysis of infliximab intensification in acute severe ulcerative colitis.

Inflammatory bowel diseases·2026
Same author

Quality of healthcare delivery in inflammatory bowel disease pregnancy: a scoping review.

Inflammatory bowel diseases·2026
Same author

Monocyte Distribution Width Differentiates Bacterial Enterocolitis from Acute Severe Ulcerative Colitis in the Emergency Department.

Digestive diseases and sciences·2026
Same author

Reply.

Gastroenterology·2026

Related Experiment Video

Updated: Jun 27, 2025

Systematic Scoring Analysis for Intestinal Inflammation in a Murine Dextran Sodium Sulfate-Induced Colitis Model
09:11

Systematic Scoring Analysis for Intestinal Inflammation in a Murine Dextran Sodium Sulfate-Induced Colitis Model

Published on: February 14, 2021

9.3K

Defining management strategies for acute severe ulcerative colitis using predictive models: a simulation-modeling

Danny Con1, Peter De Cruz1,2

  • 1Department of Gastroenterology, Austin Health, Heidelberg, Australia.

Intestinal Research
|May 7, 2024
PubMed
Summary
This summary is machine-generated.

Predictive models can guide treatment for acute severe ulcerative colitis (ASUC) refractory to infliximab. Optimized strategies significantly reduce colectomy rates by stratifying patients for advanced therapies, improving outcomes.

Keywords:
ColectomyInflammatory bowel diseasesInfliximabTumor necrosis factor-alpha

More Related Videos

Author Spotlight: Liujunzi Decoction as a Traditional Chinese Treatment for Coloproctitis Cancer
06:24

Author Spotlight: Liujunzi Decoction as a Traditional Chinese Treatment for Coloproctitis Cancer

Published on: October 13, 2023

879
Murine Appendectomy Model of Chronic Colitis Associated Colorectal Cancer by Precise Localization of Caecal Patch
00:08

Murine Appendectomy Model of Chronic Colitis Associated Colorectal Cancer by Precise Localization of Caecal Patch

Published on: August 24, 2019

10.0K

Related Experiment Videos

Last Updated: Jun 27, 2025

Systematic Scoring Analysis for Intestinal Inflammation in a Murine Dextran Sodium Sulfate-Induced Colitis Model
09:11

Systematic Scoring Analysis for Intestinal Inflammation in a Murine Dextran Sodium Sulfate-Induced Colitis Model

Published on: February 14, 2021

9.3K
Author Spotlight: Liujunzi Decoction as a Traditional Chinese Treatment for Coloproctitis Cancer
06:24

Author Spotlight: Liujunzi Decoction as a Traditional Chinese Treatment for Coloproctitis Cancer

Published on: October 13, 2023

879
Murine Appendectomy Model of Chronic Colitis Associated Colorectal Cancer by Precise Localization of Caecal Patch
00:08

Murine Appendectomy Model of Chronic Colitis Associated Colorectal Cancer by Precise Localization of Caecal Patch

Published on: August 24, 2019

10.0K

Area of Science:

  • Gastroenterology
  • Clinical Informatics
  • Computational Biology

Background:

  • Acute severe ulcerative colitis (ASUC) management requires improved strategies to minimize colectomy risk in patients unresponsive to infliximab.
  • Standard infliximab induction therapy leaves a significant residual risk of colectomy.

Purpose of the Study:

  • To evaluate the efficacy of predictive model-driven management strategies for ASUC.
  • To assess the impact of varying prediction model accuracy on colectomy rates.

Main Methods:

  • A simulation study modeled 5,000 patients with steroid-refractory ASUC undergoing infliximab induction.
  • Predictive models were used to risk-stratify patients for escalated treatment.
  • The primary endpoint was the 3-month colectomy rate.

Main Results:

  • A base scenario without predictive modeling showed a 23% colectomy rate.
  • An optimized strategy using a 90% AUC prediction model reduced colectomy to 8% (65% risk reduction).
  • A less accurate model (80% AUC) reduced colectomy to 15% (35% risk reduction), highlighting dependence on model accuracy and treatment efficacy.

Conclusions:

  • This study demonstrates the potential of simulated predictive model-based strategies in ASUC management.
  • Accurate predictive models are crucial for optimizing treatment escalation and reducing colectomy rates.
  • Future research should integrate simulation studies for predictive model development in ASUC.